significantnew treatment
Canakinumab receives EMA approval for Still's disease including AOSD
Adult-Onset Still's Disease →Summary
Canakinumab (Ilaris) received EMA conditional marketing authorization for the treatment of Still's disease, covering both systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease. This represents the first specifically approved biologic for AOSD in Europe, supported by the CONSIDER phase II RCT and extensive sJIA data. Note: FDA approved canakinumab for sJIA in 2013 but has not granted a separate AOSD indication.
Related treatments
More from Adult-Onset Still's Disease
significantnew treatment
Anakinra confirmed superior to DMARDs in systemic AOSD: ANAKINRA-STILLS trial
landmarkDiagnostic advance
2023 ACR/EULAR classification criteria for Still's disease published
significantMechanism
Gasdermin D and pyroptosis established as central to AOSD cytokine storm
incrementalnew treatment
JAK inhibitors show early promise in refractory AOSD
ID: adult-onset-stills-disease-update-0Type: new_treatmentImpact: significant